According to CNBC, the agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

Ars Technica reported that the risk appears small and data is mixed, but FDA wants patients to be aware.

This brief draws on reporting by CNBC and Ars Technica.